CSF somatostatin increase in patients with early parkinsonian syndrome
Identifieur interne : 001479 ( Main/Corpus ); précédent : 001478; suivant : 001480CSF somatostatin increase in patients with early parkinsonian syndrome
Auteurs : A. Espino ; M. Calopa ; S. Ambrosio ; J. Ortolà ; J. Peres ; A. NavarroSource :
- Journal of Neural Transmission - Parkinson's Disease and Dementia Section [ 0936-3076 ] ; 1995-06-01.
Abstract
Summary: Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.
Url:
DOI: 10.1007/BF02259660
Links to Exploration step
ISTEX:9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">CSF somatostatin increase in patients with early parkinsonian syndrome</title><author><name sortKey="Espino, A" sort="Espino, A" uniqKey="Espino A" first="A." last="Espino">A. Espino</name><affiliation><mods:affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Calopa, M" sort="Calopa, M" uniqKey="Calopa M" first="M." last="Calopa">M. Calopa</name><affiliation><mods:affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author><author><name sortKey="Ambrosio, S" sort="Ambrosio, S" uniqKey="Ambrosio S" first="S." last="Ambrosio">S. Ambrosio</name><affiliation><mods:affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Ortola, J" sort="Ortola, J" uniqKey="Ortola J" first="J." last="Ortolà">J. Ortolà</name><affiliation><mods:affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author><author><name sortKey="Peres, J" sort="Peres, J" uniqKey="Peres J" first="J." last="Peres">J. Peres</name><affiliation><mods:affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author><author><name sortKey="Navarro, A" sort="Navarro, A" uniqKey="Navarro A" first="A." last="Navarro">A. Navarro</name><affiliation><mods:affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1007/BF02259660</idno><idno type="url">https://api.istex.fr/document/9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001479</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">CSF somatostatin increase in patients with early parkinsonian syndrome</title><author><name sortKey="Espino, A" sort="Espino, A" uniqKey="Espino A" first="A." last="Espino">A. Espino</name><affiliation><mods:affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Calopa, M" sort="Calopa, M" uniqKey="Calopa M" first="M." last="Calopa">M. Calopa</name><affiliation><mods:affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author><author><name sortKey="Ambrosio, S" sort="Ambrosio, S" uniqKey="Ambrosio S" first="S." last="Ambrosio">S. Ambrosio</name><affiliation><mods:affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Ortola, J" sort="Ortola, J" uniqKey="Ortola J" first="J." last="Ortolà">J. Ortolà</name><affiliation><mods:affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author><author><name sortKey="Peres, J" sort="Peres, J" uniqKey="Peres J" first="J." last="Peres">J. Peres</name><affiliation><mods:affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author><author><name sortKey="Navarro, A" sort="Navarro, A" uniqKey="Navarro A" first="A." last="Navarro">A. Navarro</name><affiliation><mods:affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><title level="j" type="abbrev">J Neural Transm Gen Sect</title><idno type="ISSN">0936-3076</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1995-06-01">1995-06-01</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">2-3</biblScope><biblScope unit="page" from="189">189</biblScope><biblScope unit="page" to="196">196</biblScope></imprint><idno type="ISSN">0936-3076</idno></series><idno type="istex">9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9</idno><idno type="DOI">10.1007/BF02259660</idno><idno type="ArticleID">Art9</idno><idno type="ArticleID">BF02259660</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0936-3076</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>Dr. A. Espino</name><affiliations><json:string>Department of Neurology, Hospital Prínceps d'Espanya, Spain</json:string><json:string>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>M. Calopa</name><affiliations><json:string>Department of Neurology, Hospital Prínceps d'Espanya, Spain</json:string></affiliations></json:item><json:item><name>S. Ambrosio</name><affiliations><json:string>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>J. Ortolà</name><affiliations><json:string>Hormone Unit, Hospital Prínceps d'Espanya, Spain</json:string></affiliations></json:item><json:item><name>J. Peres</name><affiliations><json:string>Department of Neurology, Hospital Prínceps d'Espanya, Spain</json:string></affiliations></json:item><json:item><name>M. A. Navarro</name><affiliations><json:string>Hormone Unit, Hospital Prínceps d'Espanya, Spain</json:string></affiliations></json:item></author><articleId><json:string>Art9</json:string><json:string>BF02259660</json:string></articleId><language><json:string>eng</json:string></language><abstract>Summary: Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.</abstract><qualityIndicators><score>5.957</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 774 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1280</abstractCharCount><pdfWordCount>3749</pdfWordCount><pdfCharCount>19374</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>184</abstractWordCount></qualityIndicators><title>CSF somatostatin increase in patients with early parkinsonian syndrome</title><genre><json:string>research-article</json:string></genre><host><volume>9</volume><pages><last>196</last><first>189</first></pages><issn><json:string>0936-3076</json:string></issn><issue>2-3</issue><subject><json:item><value>Pharmacology/Toxicology</value></json:item><json:item><value>Psychiatry</value></json:item><json:item><value>Neurology</value></json:item></subject><journalId><json:string>722</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1435-1463</json:string></eissn><title>Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate></host><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1007/BF02259660</json:string></doi><id>9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">CSF somatostatin increase in patients with early parkinsonian syndrome</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><availability><p>SPRINGER</p></availability><date>1994-07-11</date></publicationStmt><notesStmt><note>Full Papers</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">CSF somatostatin increase in patients with early parkinsonian syndrome</title><author><persName><forename type="first">A.</forename><surname>Espino</surname></persName><roleName type="degree">Dr.</roleName><affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</affiliation><affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</affiliation></author><author><persName><forename type="first">M.</forename><surname>Calopa</surname></persName><affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</affiliation></author><author><persName><forename type="first">S.</forename><surname>Ambrosio</surname></persName><affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</affiliation></author><author><persName><forename type="first">J.</forename><surname>Ortolà</surname></persName><affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</affiliation></author><author><persName><forename type="first">J.</forename><surname>Peres</surname></persName><affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</affiliation></author><author><persName><forename type="first">M.</forename><surname>Navarro</surname></persName><affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</affiliation></author></analytic><monogr><title level="j">Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title><title level="j" type="abbrev">J Neural Transm Gen Sect</title><idno type="JournalID">722</idno><idno type="pISSN">0936-3076</idno><idno type="eISSN">1435-1463</idno><idno type="IssueArticleCount">16</idno><idno type="VolumeIssueCount">3</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1995-06-01"></date><biblScope unit="volume">9</biblScope><biblScope unit="issue">2-3</biblScope><biblScope unit="page" from="189">189</biblScope><biblScope unit="page" to="196">196</biblScope></imprint></monogr><idno type="istex">9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9</idno><idno type="DOI">10.1007/BF02259660</idno><idno type="ArticleID">Art9</idno><idno type="ArticleID">BF02259660</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1994-07-11</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Pharmacology/Toxicology</term></item><item><term>Psychiatry</term></item><item><term>Neurology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994-07-11">Created</change><change when="1995-06-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Vienna</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>722</JournalID><JournalPrintISSN>0936-3076</JournalPrintISSN><JournalElectronicISSN>1435-1463</JournalElectronicISSN><JournalTitle>Journal of Neural Transmission - Parkinson's Disease and Dementia Section</JournalTitle><JournalAbbreviatedTitle>J Neural Transm Gen Sect</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Pharmacology/Toxicology</JournalSubject><JournalSubject Type="Secondary">Psychiatry</JournalSubject><JournalSubject Type="Secondary">Neurology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>9</VolumeIDStart><VolumeIDEnd>9</VolumeIDEnd><VolumeIssueCount>3</VolumeIssueCount></VolumeInfo><Issue IssueType="Combined"><IssueInfo TocLevels="0"><IssueIDStart>2</IssueIDStart><IssueIDEnd>3</IssueIDEnd><IssueArticleCount>16</IssueArticleCount><IssueHistory><CoverDate><DateString>1995</DateString><Year>1995</Year><Month>6</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1995</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art9"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF02259660</ArticleID><ArticleDOI>10.1007/BF02259660</ArticleDOI><ArticleSequenceNumber>9</ArticleSequenceNumber><ArticleTitle Language="En">CSF somatostatin increase in patients with early parkinsonian syndrome</ArticleTitle><ArticleCategory>Full Papers</ArticleCategory><ArticleFirstPage>189</ArticleFirstPage><ArticleLastPage>196</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2005</Year><Month>10</Month><Day>24</Day></RegistrationDate><Received><Year>1994</Year><Month>7</Month><Day>11</Day></Received><Accepted><Year>1994</Year><Month>9</Month><Day>26</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1995</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>722</JournalID><VolumeIDStart>9</VolumeIDStart><VolumeIDEnd>9</VolumeIDEnd><IssueIDStart>2</IssueIDStart><IssueIDEnd>3</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1 Aff2" PresentAffiliationID="Aff2"><AuthorName DisplayOrder="Western"><Prefix>Dr.</Prefix><GivenName>A.</GivenName><FamilyName>Espino</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Calopa</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>S.</GivenName><FamilyName>Ambrosio</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>J.</GivenName><FamilyName>Ortolà</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>J.</GivenName><FamilyName>Peres</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><GivenName>A.</GivenName><FamilyName>Navarro</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Department of Neurology</OrgDivision><OrgName>Hospital Prínceps d'Espanya</OrgName><OrgAddress><Country>Spain</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Hormone Unit</OrgDivision><OrgName>Hospital Prínceps d'Espanya</OrgName><OrgAddress><Country>Spain</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Unitat de Bioquímica</OrgDivision><OrgName>Facultat d'Odontologia</OrgName><OrgAddress><Street>C/Feixa Llarga s/n</Street><Postcode>08907</Postcode><City>L'Hospitalet, Barcelona</City><Country>Spain</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.</Para></Abstract><KeywordGroup Language="En"><Heading>Keywords</Heading><Keyword>Parkinsonian syndrome</Keyword><Keyword>Parkinson's disease</Keyword><Keyword>somatostatin-like immunoreactivity</Keyword><Keyword>homovanillic acid</Keyword><Keyword>cerebrospinal fluid</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>CSF somatostatin increase in patients with early parkinsonian syndrome</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>CSF somatostatin increase in patients with early parkinsonian syndrome</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="given">A.</namePart><namePart type="family">Espino</namePart><affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</affiliation><affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Calopa</namePart><affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Ambrosio</namePart><affiliation>Unitat de Bioquímica, Facultat d'Odontologia, C/Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Ortolà</namePart><affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Peres</namePart><affiliation>Department of Neurology, Hospital Prínceps d'Espanya, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="given">A.</namePart><namePart type="family">Navarro</namePart><affiliation>Hormone Unit, Hospital Prínceps d'Espanya, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Vienna</placeTerm></place><dateCreated encoding="w3cdtf">1994-07-11</dateCreated><dateIssued encoding="w3cdtf">1995-06-01</dateIssued><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: Somatostatin-like immunoreactivity levels (SLI) in cerebrospinal fluid (CSF) were determined in twenty-three patients with untreated parkinsonian syndrome (15 with Idiopathic Parkinson's disease (IPD) and 8 with other forms of parkinsonism) at the moment of clinical diagnosis (mean duration of disease 1.1±0.2 years), and in 26 subjects without neurological symptoms. None of the IPD patients had a diagnosis of dementia at the moment of inclusion in the study. CSF-SLI content was found to be significantly higher in patients with parkinsonian syndrome (107.9±9.8 pg/ml) than in control subjects (73.5±8.4 pg/ml). The increase was also significant when controls were compared with IPD patients. In addition, a positive correlation between SLI and homovanillic acid was found in CSF of all patients. A test of learning memory was used to evaluate the mental state of patients and a significant increase in CSF-somatostatin levels was observed in patients with Idiopathic Parkinson's disease and severe affectation of memory. These results indicate that in the early steps of untreated parkinsonian syndrome, somatostatin concentration in cerebrospinal fluid may increase, probably due to the neurodegenerative depletion of somatostatin from striatal or cortical neurons.</abstract><note>Full Papers</note><relatedItem type="host"><titleInfo><title>Journal of Neural Transmission - Parkinson's Disease and Dementia Section</title></titleInfo><titleInfo type="abbreviated"><title>J Neural Transm Gen Sect</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1995-06-01</dateIssued><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Pharmacology/Toxicology</topic><topic>Psychiatry</topic><topic>Neurology</topic></subject><identifier type="ISSN">0936-3076</identifier><identifier type="eISSN">1435-1463</identifier><identifier type="JournalID">722</identifier><identifier type="IssueArticleCount">16</identifier><identifier type="VolumeIssueCount">3</identifier><part><date>1995</date><detail type="volume"><number>9</number><caption>vol.</caption></detail><detail type="issue"><number>2-3</number><caption>no.</caption></detail><extent unit="pages"><start>189</start><end>196</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1995</recordOrigin></recordInfo></relatedItem><identifier type="istex">9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9</identifier><identifier type="DOI">10.1007/BF02259660</identifier><identifier type="ArticleID">Art9</identifier><identifier type="ArticleID">BF02259660</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1995</recordOrigin></recordInfo></mods></metadata><enrichments><istex:refBibTEI uri="https://api.istex.fr/document/9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9/enrichments/refBib"><teiHeader></teiHeader><text><front></front><body></body><back><listBibl><biblStruct xml:id="b0"><analytic><title level="a" type="main">Application of the dual-cell coulometric detector: a method for assaying monoamines and their metabolites</title><author><persName><forename type="first">G</forename><surname>Achilli</surname></persName></author><author><persName><forename type="first">C</forename><surname>Perego</surname></persName></author><author><persName><forename type="first">F</forename><surname>Ponzio</surname></persName></author></analytic><monogr><title level="j">Anal Biochem</title><imprint><biblScope unit="volume">148</biblScope><biblScope unit="page" from="1" to="9"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct xml:id="b1"><analytic><title level="a" type="main">Biochemistry of Parkinson's disease 28 years later: a critical review</title><author><persName><forename type="first">Y</forename><surname>Agid</surname></persName></author><author><persName><forename type="first">P</forename><surname>Cervera</surname></persName></author><author><persName><forename type="first">E</forename><surname>Hirsch</surname></persName></author><author><persName><forename type="first">F</forename><surname>Javoy-Agid</surname></persName></author><author><persName><forename type="first">S</forename><surname>Lehericy</surname></persName></author><author><persName><forename type="first">R</forename><surname>Raisman</surname></persName></author><author><persName><forename type="first">M</forename><surname>Ruberg</surname></persName></author></analytic><monogr><title level="j">Mov Disord</title><imprint><biblScope unit="volume">41</biblScope><biblScope unit="page" from="126" to="144"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct xml:id="b2"><analytic><title level="a" type="main">Radioimmunoassay of GH-release inhibiting hormone</title><author><persName><forename type="first">A</forename><surname>Arimura</surname></persName></author><author><persName><forename type="first">H</forename><surname>Sato</surname></persName></author><author><persName><forename type="first">Dh</forename><surname>Coy</surname></persName></author><author><persName><forename type="first">Av</forename><surname>Schally</surname></persName></author></analytic><monogr><title level="j">Proc Soc Exp Biol Med</title><imprint><biblScope unit="volume">148</biblScope><biblScope unit="page">784</biblScope><date type="published" when="1975"></date></imprint></monogr></biblStruct><biblStruct xml:id="b3"><analytic><title level="a" type="main">The effect of somatostatin on striatal catecholamines</title><author><persName><forename type="first">Mf</forename><surname>Beal</surname></persName></author><author><persName><forename type="first">Jb</forename><surname>Martin</surname></persName></author></analytic><monogr><title level="j">Neurosci Lett</title><imprint><biblScope unit="volume">44</biblScope><biblScope unit="page" from="271" to="276"></biblScope><date type="published" when="1984"></date></imprint></monogr></biblStruct><biblStruct xml:id="b4"><analytic><title level="a" type="main">Human cerebrospinal fluid somatostatin in neurologic disease</title><author><persName><forename type="first">Mf</forename><surname>Beal</surname></persName></author><author><persName><forename type="first">Mf</forename><surname>Mazurek</surname></persName></author><author><persName><forename type="first">P</forename><surname>Black</surname></persName></author><author><persName><forename type="first">Jb</forename><surname>Martin</surname></persName></author></analytic><monogr><title level="j">J Neurol Sci</title><imprint><biblScope unit="volume">71</biblScope><biblScope unit="page" from="91" to="104"></biblScope><date type="published" when="1985"></date></imprint></monogr></biblStruct><biblStruct xml:id="b5"><analytic><title level="a" type="main">CSF somatostatin-like immunoreactivity in dementia</title><author><persName><forename type="first">Mf</forename><surname>Beal</surname></persName></author><author><persName><forename type="first">Jh</forename><surname>Growdon</surname></persName></author><author><persName><forename type="first">Mf</forename><surname>Mazurek</surname></persName></author><author><persName><forename type="first">Jb</forename><surname>Martin</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">36</biblScope><biblScope unit="page" from="294" to="297"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b6"><analytic><title level="a" type="main">Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes</title><author><persName><forename type="first">Mf</forename><surname>Beal</surname></persName></author><author><persName><forename type="first">Mf</forename><surname>Mazurek</surname></persName></author><author><persName><forename type="first">Jb</forename><surname>Martin</surname></persName></author></analytic><monogr><title level="j">Brain Res</title><imprint><biblScope unit="volume">397</biblScope><biblScope unit="page" from="386" to="388"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b7"><analytic><title level="a" type="main">An inventory for measuring depression</title><author><persName><forename type="first">At</forename><surname>Beck</surname></persName></author><author><persName><forename type="first">Ch</forename><surname>Ward</surname></persName></author><author><persName><forename type="first">M</forename><surname>Mendelson</surname></persName></author><author><persName><forename type="first">J</forename><surname>Mock</surname></persName></author><author><persName><forename type="first">J</forename><surname>Erbaugh</surname></persName></author></analytic><monogr><title level="j">Arch Gen Psychiatry</title><imprint><biblScope unit="volume">4</biblScope><biblScope unit="page" from="561" to="571"></biblScope><date type="published" when="1961"></date></imprint></monogr></biblStruct><biblStruct xml:id="b8"><analytic><title level="a" type="main">Minireview: somatostatin in Alzheimer's disease and depression</title><author><persName><forename type="first">G</forename><surname>Bisette</surname></persName></author><author><persName><forename type="first">B</forename><surname>Myers</surname></persName></author></analytic><monogr><title level="j">Life Sci</title><imprint><biblScope unit="volume">51</biblScope><biblScope unit="page" from="1389" to="1410"></biblScope><date type="published" when="1992"></date></imprint></monogr></biblStruct><biblStruct xml:id="b9"><analytic><title level="a" type="main">Criteria for diagnosing Parkinson's disease</title><author><persName><forename type="first">Db</forename><surname>Calne</surname></persName></author><author><persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Snow</surname></persName></author><author><persName><forename type="first">C</forename><surname>Lee</surname></persName></author></analytic><monogr><title level="j">Ann Neurol</title><imprint><biblScope unit="volume">32</biblScope><biblScope unit="page" from="125" to="127"></biblScope><date type="published" when="1992"></date></imprint></monogr></biblStruct><biblStruct xml:id="b10"><analytic><title level="a" type="main">Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei</title><author><persName><forename type="first">Mf</forename><surname>Chesselet</surname></persName></author><author><persName><forename type="first">Td</forename><surname>Reisine</surname></persName></author></analytic><monogr><title level="j">J Neurosci</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page" from="232" to="236"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct xml:id="b11"><analytic><title level="a" type="main">Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease</title><author><persName><forename type="first">L-G</forename><surname>Chia</surname></persName></author><author><persName><forename type="first">F-C</forename><surname>Cheng</surname></persName></author><author><persName><forename type="first">J-S</forename><surname>Kuo</surname></persName></author></analytic><monogr><title level="j">J Neurol Sci</title><imprint><biblScope unit="volume">116</biblScope><biblScope unit="page" from="125" to="134"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b12"><analytic><title level="a" type="main">Functional in vivo interaction between growth hormone and dopamine systems are correlated to changes in striatal somatostatin levels as detected by voltammetry</title><author><persName><forename type="first">F</forename><surname>Crespi</surname></persName></author></analytic><monogr><title level="j">Exp Brain Res</title><imprint><biblScope unit="volume">94</biblScope><biblScope unit="page" from="363" to="370"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b13"><analytic><title level="a" type="main">Low cerebral fluid somatostatin in Parkinson disease: an irreversible abnormality</title><author><persName><forename type="first">E</forename><surname>Dupont</surname></persName></author><author><persName><forename type="first">Se</forename><surname>Christensen</surname></persName></author><author><persName><forename type="first">Ap</forename><surname>Hansen</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">32</biblScope><biblScope unit="page" from="312" to="314"></biblScope><date type="published" when="1982"></date></imprint></monogr></biblStruct><biblStruct xml:id="b14"><analytic><title level="a" type="main">Somatostatin and dementia in Parkinson's disease</title><author><persName><forename type="first">J</forename><surname>Epelbaum</surname></persName></author><author><persName><forename type="first">M</forename><surname>Ruberg</surname></persName></author><author><persName><forename type="first">E</forename><surname>Moyse</surname></persName></author><author><persName><forename type="first">F</forename><surname>Jovoy-Agid</surname></persName></author><author><persName><forename type="first">B</forename><surname>Dubois</surname></persName></author><author><persName><forename type="first">Y</forename><surname>Agid</surname></persName></author></analytic><monogr><title level="j">Brain Res</title><imprint><biblScope unit="volume">278</biblScope><biblScope unit="page" from="376" to="379"></biblScope><date type="published" when="1983"></date></imprint></monogr></biblStruct><biblStruct xml:id="b15"><analytic><title level="a" type="main">Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+</title><author><persName><forename type="first">A</forename><surname>Espino</surname></persName></author><author><persName><forename type="first">S</forename><surname>Ambrosio</surname></persName></author><author><persName><forename type="first">R</forename><surname>Bartrons</surname></persName></author><author><persName><forename type="first">G</forename><surname>Bendahan</surname></persName></author><author><persName><forename type="first">M</forename><surname>Calopa</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">7</biblScope><biblScope unit="page" from="167" to="176"></biblScope><date type="published" when="1994"></date></imprint></monogr></biblStruct><biblStruct xml:id="b16"><analytic><title level="a" type="main">Reaction time in Parkinson's disease</title><author><persName><forename type="first">Ev</forename><surname>Evarts</surname></persName></author><author><persName><forename type="first">H</forename><surname>Tersv~iinen</surname></persName></author><author><persName><forename type="first">Db</forename><surname>Calne</surname></persName></author></analytic><monogr><title level="j">Brain</title><imprint><biblScope unit="volume">104</biblScope><biblScope unit="page" from="167" to="186"></biblScope><date type="published" when="1981"></date></imprint></monogr></biblStruct><biblStruct xml:id="b17"><analytic><title level="a" type="main">Opiate receptor mediated changes in monoamine synthesis in rat brain</title><author><persName><forename type="first">Garcia</forename><surname>Sevilla</surname></persName></author><author><persName><forename type="first">Ja</forename><surname>Athee</surname></persName></author><author><persName><forename type="first">L</forename><surname>Magnusson</surname></persName></author><author><persName><forename type="first">T</forename><surname>Carlsson</surname></persName></author><author><persName><forename type="first">A</forename></persName></author></analytic><monogr><title level="j">Pharm Pharmacol</title><imprint><biblScope unit="volume">30</biblScope><biblScope unit="page" from="613" to="621"></biblScope><date type="published" when="1978"></date></imprint></monogr></biblStruct><biblStruct xml:id="b18"><analytic><title level="a" type="main">Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors</title><author><persName><forename type="first">P</forename><surname>Hartikainen</surname></persName></author><author><persName><forename type="first">H</forename><surname>Soininen</surname></persName></author><author><persName><forename type="first">Kj</forename><surname>Reinikainen</surname></persName></author><author><persName><forename type="first">J</forename><surname>Sirvi6</surname></persName></author><author><persName><forename type="first">R</forename><surname>Soikkeli</surname></persName></author><author><persName><forename type="first">Pj</forename><surname>Riekkinen</surname></persName></author></analytic><monogr><title level="j">J Neural Transm [GenSect]</title><imprint><biblScope unit="volume">84</biblScope><biblScope unit="page" from="103" to="117"></biblScope><date type="published" when="1991"></date></imprint></monogr></biblStruct><biblStruct xml:id="b19"><analytic><title level="a" type="main">Parkinsonism: onset, progression and mortality</title><author><persName><forename type="first">Mm</forename><surname>Hoehn</surname></persName></author><author><persName><forename type="first">Md</forename><surname>Yahr</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">17</biblScope><biblScope unit="page" from="427" to="442"></biblScope><date type="published" when="1967"></date></imprint></monogr></biblStruct><biblStruct xml:id="b20"><analytic><title level="a" type="main">Magnetic resonance imaging in dementia of Parkinson's disease</title><author><persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Huber</surname></persName></author><author><persName><forename type="first">Ec</forename><surname>Shutteleworth</surname></persName></author><author><persName><forename type="first">Ja</forename><surname>Christy</surname></persName></author><author><persName><forename type="first">Dw</forename><surname>Chakeres</surname></persName></author><author><persName><forename type="first">A</forename><surname>Curtin</surname></persName></author><author><persName><forename type="first">Gw</forename><surname>Paulson</surname></persName></author></analytic><monogr><title level="j">J Neurol Neurosurg Psychiatry</title><imprint><biblScope unit="volume">52</biblScope><biblScope unit="page" from="1221" to="1227"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct xml:id="b21"><analytic><title level="a" type="main">Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases</title><author><persName><forename type="first">Aj</forename><surname>Hugues</surname></persName></author><author><persName><forename type="first">Se</forename><surname>Daniel</surname></persName></author><author><persName><forename type="first">L</forename><surname>Kilford</surname></persName></author><author><persName><forename type="first">Aj</forename><surname>Lees</surname></persName></author></analytic><monogr><title level="j">J Neurol Neurosurg Psychiatry</title><imprint><biblScope unit="volume">55</biblScope><biblScope unit="page" from="181" to="184"></biblScope><date type="published" when="1992"></date></imprint></monogr></biblStruct><biblStruct xml:id="b22"><monogr><title level="m" type="main">Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with A</title><author><persName><forename type="first">J</forename><surname>Jolkkonen</surname></persName></author><author><persName><forename type="first">H</forename><surname>Soininen</surname></persName></author><author><persName><forename type="first">T</forename><surname>Halonen</surname></persName></author><author><persName><forename type="first">A</forename><surname>Ylinen</surname></persName></author><author><persName><forename type="first">V</forename><surname>Laulumaa</surname></persName></author><author><persName><forename type="first">M</forename><surname>Laakso</surname></persName></author><author><persName><forename type="first">P</forename><surname>Riekkinen</surname></persName></author><imprint><date type="published" when="1986"></date></imprint></monogr></biblStruct><biblStruct xml:id="b23"><analytic><title level="a" type="main">Parkinson's disease and its relation to dementia</title></analytic><monogr><title level="j">J Neurol Neurosurg Psychiatry</title><imprint><biblScope unit="volume">49</biblScope><biblScope unit="page" from="1374" to="1377"></biblScope></imprint></monogr></biblStruct><biblStruct xml:id="b24"><analytic><title level="a" type="main">Ventricular fluid neuropeptides in Parkinson's disease</title><author><persName><forename type="first">S</forename><surname>Jost</surname></persName></author><author><persName><forename type="first">C</forename><surname>Reuner</surname></persName></author><author><persName><forename type="first">M</forename><surname>Mohadjer</surname></persName></author><author><persName><forename type="first">F</forename><surname>Mundinger</surname></persName></author><author><persName><forename type="first">H</forename><surname>Cramer</surname></persName></author></analytic><monogr><title level="j">Neuropeptides</title><imprint><biblScope unit="volume">15</biblScope><biblScope unit="page" from="219" to="225"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b25"><analytic><title level="a" type="main">Assesment of Parkinson's disease Quantification of neurologic deficit</title><author><persName><forename type="first">Ae</forename><surname>Lang</surname></persName></author><author><persName><forename type="first">S</forename><surname>Fann</surname></persName></author></analytic><monogr><title level="j">Butterworths</title><editor>Munsat TL</editor><imprint><biblScope unit="page" from="285" to="309"></biblScope><date type="published" when="1989"></date></imprint></monogr></biblStruct><biblStruct xml:id="b26"><analytic><title level="a" type="main">Markers of dopamine metabolism in Parkinson's disease</title><author><persName><forename type="first">Pa</forename><surname>Lewitt</surname></persName></author><author><persName><forename type="first">Mp</forename><surname>Galloway</surname></persName></author><author><persName><forename type="first">W</forename><surname>Matson</surname></persName></author><author><persName><forename type="first">P</forename><surname>Milbury</surname></persName></author><author><persName><forename type="first">M</forename><surname>Mcdermott</surname></persName></author><author><persName><forename type="first">Dk</forename><surname>Srivastava</surname></persName></author><author><persName><forename type="first">D</forename><surname>Oakes</surname></persName></author><author><persName><surname>Parkinson Study</surname></persName></author><author><persName><surname>Group</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">42</biblScope><biblScope unit="page" from="2111" to="2117"></biblScope><date type="published" when="1992"></date></imprint></monogr></biblStruct><biblStruct xml:id="b27"><analytic><title level="a" type="main">Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy</title><author><persName><forename type="first">H</forename><surname>Masson</surname></persName></author><author><persName><forename type="first">I</forename><surname>Popescu</surname></persName></author><author><persName><forename type="first">D</forename><surname>Strubel</surname></persName></author><author><persName><forename type="first">H</forename><surname>Cramer</surname></persName></author><author><persName><forename type="first">F</forename><surname>Kuntzmann</surname></persName></author></analytic><monogr><title level="j">J Am Geriatr Soc</title><imprint><biblScope unit="volume">38</biblScope><biblScope unit="page" from="19" to="24"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b28"><analytic><title level="a" type="main">CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease</title><author><persName><forename type="first">W</forename><surname>Poewe</surname></persName></author><author><persName><forename type="first">T</forename><surname>Benke</surname></persName></author><author><persName><forename type="first">E</forename><surname>Karamat</surname></persName></author><author><persName><forename type="first">L</forename><surname>Schelosky</surname></persName></author><author><persName><forename type="first">M</forename><surname>Wagner</surname></persName></author></analytic><monogr><title level="j">J Neurol Neurosurg Psychiatry</title><imprint><biblScope unit="volume">53</biblScope><biblScope unit="page" from="1105" to="1106"></biblScope><date type="published" when="1990"></date></imprint></monogr></biblStruct><biblStruct xml:id="b29"><analytic><title level="a" type="main">The significance of cerebral atrophy for the symptomatology of Parkinson's disease</title><author><persName><forename type="first">Rey A Paris</forename><surname>Schneider</surname></persName></author><author><persName><forename type="first">E</forename><surname>Fischer</surname></persName></author><author><persName><forename type="first">P</forename><surname>Jacobi</surname></persName></author><author><persName><forename type="first">P</forename><surname>Becker</surname></persName></author><author><persName><forename type="first">H</forename><surname>Harker</surname></persName></author><author><persName><forename type="first">H</forename></persName></author></analytic><monogr><title level="j">J Neurol Sci</title><imprint><biblScope unit="volume">42</biblScope><biblScope unit="page" from="187" to="197"></biblScope><date type="published" when="1964"></date></imprint></monogr></biblStruct><biblStruct xml:id="b30"><analytic><title level="a" type="main">Parkinson's disease and dementia: clinical and neurochemical correlations</title><author><persName><forename type="first">Mm</forename><surname>Strittmatter</surname></persName></author><author><persName><forename type="first">H</forename><surname>Cramer</surname></persName></author></analytic><monogr><title level="j">Neuroreport</title><imprint><biblScope unit="volume">3</biblScope><biblScope unit="page" from="413" to="416"></biblScope><date type="published" when="1992"></date></imprint></monogr></biblStruct><biblStruct xml:id="b31"><analytic><title level="a" type="main">Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes</title><author><persName><forename type="first">H</forename><surname>Tohgi</surname></persName></author><author><persName><forename type="first">T</forename><surname>Abe</surname></persName></author><author><persName><forename type="first">S</forename><surname>Takahashi</surname></persName></author><author><persName><forename type="first">Y</forename><surname>Nozaki</surname></persName></author><author><persName><forename type="first">M</forename><surname>Ueno</surname></persName></author><author><persName><forename type="first">T</forename><surname>Kikuchi</surname></persName></author></analytic><monogr><title level="j">J Neural Transm</title><imprint><biblScope unit="volume">5</biblScope><biblScope unit="page" from="17" to="26"></biblScope><date type="published" when="1993"></date></imprint></monogr></biblStruct><biblStruct xml:id="b32"><analytic><title level="a" type="main">CSF cyclic nucleotides and somatostatin in Parkinson's disease</title><author><persName><forename type="first">L</forename><surname>Volicer</surname></persName></author><author><persName><forename type="first">Mf</forename><surname>Beal</surname></persName></author><author><persName><forename type="first">Lk</forename><surname>Direnfeld</surname></persName></author><author><persName><forename type="first">Jk</forename><surname>Marquis</surname></persName></author><author><persName><forename type="first">Ml</forename><surname>Albert</surname></persName></author></analytic><monogr><title level="j">Neurology</title><imprint><biblScope unit="volume">36</biblScope><biblScope unit="page" from="89" to="92"></biblScope><date type="published" when="1986"></date></imprint></monogr></biblStruct></listBibl></back></text></istex:refBibTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001479 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001479 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:9C54AF9E1BB3B00211A7AF5AA94E21A24305D7D9
|texte= CSF somatostatin increase in patients with early parkinsonian syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |